Aisling Capital as of March 31, 2016
Portfolio Holdings for Aisling Capital
Aisling Capital holds 22 positions in its portfolio as reported in the March 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Loxo Oncology | 20.8 | $104M | 3.8M | 27.34 | |
| Zeltiq Aesthetics | 11.4 | $57M | 2.1M | 27.16 | |
| Aimmune Therapeutics | 8.1 | $41M | 3.0M | 13.56 | |
| Transenterix | 7.1 | $35M | 8.3M | 4.25 | |
| Viewray (VRAYQ) | 6.4 | $32M | 7.5M | 4.30 | |
| Adma Biologics (ADMA) | 5.8 | $29M | 3.6M | 8.09 | |
| T2 Biosystems | 5.6 | $28M | 2.8M | 9.86 | |
| Esperion Therapeutics (ESPR) | 5.5 | $28M | 1.6M | 16.91 | |
| Cempra | 4.2 | $21M | 1.2M | 17.52 | |
| Dermira | 4.0 | $20M | 971k | 20.68 | |
| Catalent | 3.8 | $19M | 716k | 26.67 | |
| Agile Therapeutics | 3.7 | $19M | 3.0M | 6.21 | |
| Versartis | 3.7 | $18M | 2.3M | 8.02 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 | 2.6 | $13M | 1.0M | 12.70 | |
| Cynapsus Therapeutics | 2.4 | $12M | 1.0M | 11.90 | |
| Paratek Pharmaceuticals | 2.1 | $10M | 683k | 15.17 | |
| Intersect Ent | 1.3 | $6.7M | 350k | 19.00 | |
| Chimerix (CMRX) | 0.5 | $2.4M | 473k | 5.11 | |
| Pernix Therapeutics Holdings | 0.4 | $2.1M | 2.0M | 1.05 | |
| Lombard Med (EVARF) | 0.2 | $931k | 886k | 1.05 | |
| Pernix Therapeutics Hldgs In debt | 0.2 | $825k | 2.5M | 0.33 | |
| Roka Bioscience | 0.1 | $354k | 513k | 0.69 |
